Proteome Sciences has developed in-vitro assays to treat allergies associated with the skin and respiratory system that are induced by chemical compounds and substances.

Using PS Biomarker Services platform, Proteome identified and filed patents for more than 100 biomarkers from cells in the immune system and another 100 biomarkers from skin cells.

Proteome Sciences chief executive Christopher Pearce said that the eight TMT-SRM assays they selected have good performance and correlation with the discovery data.

"Most importantly, the biomarker assays developed provide an in-vitro alternative to animal testing that will become mandatory across the EU," Pearce said.

The company expects the biomarkers it has identified will lead to a number of industrial testing products and service contracts.